{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:18:56Z","timestamp":1781644736272,"version":"3.54.5"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0183869","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T13:41:23Z","timestamp":1504186883000},"page":"e0183869","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-6613","authenticated-orcid":true,"given":"Mohit","family":"Bhutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederica","family":"de Takacsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Stril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1155\/2010\/827281","article-title":"Canadian Thoracic Society Asthma Management Continuum\u20142010 Consensus Summary for children six years of age and over, and adults","volume":"17","author":"MD Lougheed","year":"2010","journal-title":"Can Respir J"},{"key":"ref2","first-page":"1C","article-title":"Oral corticosteroids in asthma: A review of benefits and risks","volume":"14","author":"RR Schellenberg","year":"2007","journal-title":"Can Resp J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e0133490","DOI":"10.1371\/journal.pone.0133490","article-title":"Asthma Is More Severe in Older Adults","volume":"10","author":"JG Zein","year":"2015","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"B12","DOI":"10.1038\/35037009","article-title":"The role of allergy in the development of asthma","volume":"402","author":"PG Holt","year":"1999","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3132\/pcrj.2008.00031","article-title":"The use of omalizumab in asthma","volume":"17","author":"D Price","year":"2008","journal-title":"Prim Care Respir J"},{"key":"ref6","unstructured":"Canada. N (2014) Xolair* Product Monograph."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1185\/030079907X226258","article-title":"Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis","volume":"23","author":"WW Busse","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1185\/0300799019117010","article-title":"Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality","volume":"17","author":"S Holgate","year":"2001","journal-title":"Curr Med Res Opin"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"M Humbert","year":"2005","journal-title":"Allergy"},{"key":"ref10","unstructured":"(2005) Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1164\/ajrccm.162.4.9912138","article-title":"Measuring asthma control. Clinic questionnaire or daily diary?","volume":"162","author":"EF Juniper","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"EF Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/ajrccm\/147.4.832","article-title":"Measuring quality of life in asthma","volume":"147","author":"EF Juniper","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"A Papaioannou","year":"2010","journal-title":"CMAJ"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"NA Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1183\/09059180.00001009","article-title":"Update on severe asthma: what we know and what we need","volume":"18","author":"M Gaga","year":"2009","journal-title":"Eur Respir Rev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jaip.2014.05.005","article-title":"The prevalence of severe asthma and low asthma control among Danish adults","volume":"2","author":"A von Bulow","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.02.00232001","article-title":"Costs of asthma are correlated with severity: a 1-yr prospective study","volume":"19","author":"P Godard","year":"2002","journal-title":"Eur Respir J"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.rmed.2005.06.012","article-title":"An international observational prospective study to determine the cost of asthma exacerbations (COAX)","volume":"100","author":"S Lane","year":"2006","journal-title":"Respir Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/02770903.2012.717659","article-title":"A 36-month study on the cost\/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy","volume":"49","author":"RW Dal Negro","year":"2012","journal-title":"J Asthma"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1398-9995.2008.01723.x","article-title":"An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma","volume":"63","author":"SD Sullivan","year":"2008","journal-title":"Allergy"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.98.12061322","article-title":"Costs of asthma according to the degree of severity","volume":"12","author":"J Serra-Batlles","year":"1998","journal-title":"Eur Respir J"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1398-9995.2010.02522.x","article-title":"Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma","volume":"66","author":"J Bousquet","year":"2011","journal-title":"Allergy"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":""Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study","volume":"103","author":"G Brusselle","year":"2009","journal-title":"Respir Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.rmed.2010.04.013","article-title":"Italian real-life experience of omalizumab","volume":"104","author":"M Cazzola","year":"2010","journal-title":"Respir Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1185\/030079906X148643","article-title":"Improvement in quality of life with omalizumab in patients with severe allergic asthma","volume":"22","author":"B Chipps","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/all.12815","article-title":"\u201cReal-life\u201d effectiveness of omalizumab in adult patients with severe allergic asthma: systematic review","volume":"71","author":"I Abraham","year":"2016","journal-title":"Allergy"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\u201cReal-life\u201d Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis","author":"A Alhossan","year":"2017","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0183869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:10:09Z","timestamp":1540339809000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0183869"}},"subtitle":[],"editor":[{"given":"Heinz","family":"Fehrenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0183869","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}